Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID -- Ignore unavailable to you. Want to Upgrade?

To: Bob L who wrote (1661)	5/19/1999 8:12:00 PM
From: Bob L	Respond to of 1762

One Year Cost of Treatment of Rituximab Compared to Fludarabine for Relapsed or Refractory, Low-Grade or Follicular Non-Hodgkin's Lymphoma. asco.org "Average annual costs were nearly identical for both treatments. The drug acquisition costs constituted the bulk of the total annual costs. for both agents. The lower drug acquisition cost for fludarabine was offset by the costs estimated for treating neutropenia. Few costs were incurred for the treatment of adverse events or other complications for patients treated with rituximab and the overall costs of both treatments are similar." Rituximab Induction and Maintenance Therapy in Patients (pts) with Previously Untreated Low-Grade Non-Hodgkin's Lymphoma (NHL): Preliminary Results of a Minnie Pearl Cancer Research Network Phase II Trial. asco.org "Rituximab is highly active in pts with previously untreated low-grade NHL, and may provide an excellent alternative to initial chemotherapy. Pt accrual and followup is continuing."